Introduction
Cisplatin is a widely used chemotherapy drug known for its ototoxicity. This study investigates the progression of cisplatin-related hearing loss (CRHL) in cancer survivors and its associated risk factors.
Key Findings
Hearing Loss Progression: In a cohort of 100 cancer survivors, significant hearing loss progression was noted, especially in those receiving higher doses of cisplatin.
Associated Risk Factors: Hypercholesterolemia, lower education, and severe CRHL were linked to poorer hearing performance.
Dose Interaction: Patients receiving 300 mg/m² or less experienced significantly less hearing loss progression compared to those receiving higher doses.
Conclusion
Regular audiological assessments and management of risk factors like hypercholesterolemia are crucial for cisplatin-treated cancer survivors. Tailoring follow-up care based on these findings can help mitigate hearing loss progression.
Original Study
https://doi.org/10.1001/jamaoncol.2024.1233
Leave a Reply